Pieris Pharmaceuticals, Inc.
PIRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $30 | $16 | $77 | $244 |
| - Cash | $84 | $17 | $39 | $118 |
| + Debt | $0 | $0 | $13 | $14 |
| Enterprise Value | -$53 | -$1 | $52 | $140 |
| Revenue | $0 | $43 | $26 | $31 |
| % Growth | -100% | 65.3% | -17.6% | – |
| Gross Profit | $0 | $1 | $23 | $29 |
| % Margin | – | 2.4% | 89.3% | 92.5% |
| EBITDA | $0 | -$23 | -$33 | -$46 |
| % Margin | – | -53.2% | -125.6% | -145.7% |
| Net Income | -$17 | -$25 | -$31 | -$43 |
| % Margin | – | -57.3% | -120.7% | -138% |
| EPS Diluted | -7.83 | -21.8 | -33.71 | -53.75 |
| % Growth | 64.1% | 35.3% | 37.3% | – |
| Operating Cash Flow | -$11 | -$54 | -$60 | -$8 |
| Capital Expenditures | $0 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$11 | -$54 | -$61 | -$9 |